Shots:

• Evotec to receive an up front with the total deal value of~$1B & will be eligible to receive success-based discovery development, regulatory and commercial milestone of ~$180M/program along with royalties on net sales of any products
• Lilly gets the right to select up to five programs developed from the collaboration and be responsible for the development, clinical validation, and commercialization. Evotec will lead the discovery of drug candidates
• The collaboration will use Evotec’s metabolic expertise, kidney disease patient database along with integrated data-driven drug discovery and development platforms to develop therapies for diabetes and kidney diseases

Ref: Evotec | Image: Wikipedia